drugset / Trial / NCT04689100
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
Phase 1
Unknown
259 enrolled
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.
Timeline
- Start
- 2017-04-11
- Primary completion
- 2021-12-31
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BECOTATUG | Monoclonal antibody | — | Intravenous |